FDA's rule on antibiotic trials haunts Basilea shares

Basilea shares ($BSLN) suffered today after the company disclosed that the FDA isn't backing down from its demands for two pivotal studies of its antibiotic ceftobiprole ahead of any marketing decision. Report

Suggested Articles

Johnson & Johnson faces a litany of problems, but executives are clearly not concerned—at least not about the company's short-term fortunes.

This week, Goldman Sachs resurrected a burning question: How can pharma companies profit from curing patients with one-time gene and cell therapies?

CMS has determined how it'll pay for Gilead's CAR-T cancer therapy, Yescarta, for outpatient use, but hasn't yet decided on Gilead's…